Table of Contents
1 Table Of Contents 2
1.1 List of Tables 9
1.2 List of Figures 12
2 Cancer Supportive Care Products Market: Executive Summary 15
2.1 The Global Cancer Supportive Care Products Market is Expected to Witness Sluggish Annual Growth of 2% between 2009 and 2016 15
2.2 Growth in the Bone Metastases, Oral Mucositis and Dry Mouth, and Cancer Pain Markets will Drive the Future Market Growth 16
2.3 Weak Pipeline with Very Few Promising Molecules Will Lead to Increased Dominance of Biosimilars in the Market after the Patent Expiry of Leading Biologics 16
2.4 Emerging Pharmaceutical Geographies Dominate As Areas of Concentration in the M&A and Licensing Deals for Cancer Supportive Care Products Market 17
3 Cancer Supportive Care Products Market: Introduction 19
3.1 GBI Research Report Guidance 19
4 Cancer Supportive Care Products Market: Market Overview 21
4.1 Revenue 21
4.2 Average Annual Cost of Therapy 23
4.3 Therapeutic Segmentation 25
4.4 Geographic Segmentation 27
4.5 Generic Share in the Cancer Supportive Care Products Market 32
4.6 Drivers and Restraints of Cancer Supportive Care Products Market 33
4.6.1 Drivers 33
4.6.1.1 Growth in the Markets of Bone Metastases, Cancer Pain and Oral Mucositis and Dry Mouth 33
4.6.1.2 Increase in Cancer Prevalence 34
4.6.1.3 High Unmet Need, Specifically With Respect to Drug Efficacy and Safety 34
4.6.2 Restraints 35
4.6.2.1 Patent Expiry of Leading Drugs in Major Cancer Supportive Care Products Markets 35
4.6.2.2 Weak Pipeline with Very Few Promising Molecules 35
4.6.2.3 Increased Uptake of Combination Therapies for Cancer that Reduces the Adverse Events Related to Chemotherapy 35
4.7 Unmet Needs 36
4.7.1 Efficacy 36
4.7.2 Safety 36
4.7.3 Price 37
4.8 Major Drug Classes 37
4.8.1 Anti-infectives (Oral Mucositis) 37
4.8.2 Anti-emetics (CINV) 38
4.8.3 Bisphosphonates (Bone Metastases) 39
4.8.4 Erythropoietin Stimulating Agents (CIA) 39
4.8.5 Granulocyte Colony Stimulating Factors (CINP) 40
4.8.6 Opioid Analgesics (Cancer Pain and Bone Metastases) 41
4.8.7 NSAIDs (Cancer Pain and Bone Metastases) 41
4.8.8 Monoclonal Antibodies (Bone Metastases) 41
5 Cancer Supportive Care Products Market: Therapeutic Landscape 43
5.1 Oral Mucositis and Dry Mouth Market 43
5.1.1 Introduction 43
5.1.2 Revenue 44
5.1.3 Annual Cost of Therapy 46
5.1.4 Treatment Usage Patterns 48
5.1.4.1 Prevalence Population 50
5.1.4.2 Prescription Population 51
5.1.5 Drivers for the Oral Mucositis and Dry Mouth Market 52
5.1.5.1 High Unmet Need 52
5.1.6 Restraints for the Oral Mucositis and Dry Mouth Market 53
5.1.6.1 Patent Expiries of Kepivance 53
5.1.6.2 Availability of Alternate Non-Pharmacological Treatment Options 53
5.1.7 Geographical Segmentation 53
5.2 Chemotherapy Induced Nausea and Vomiting Market 58
5.2.1 Introduction 58
5.2.2 Revenue 59
5.2.3 Annual Cost of Therapy 61
5.2.4 Treatment Usage Patterns 63
5.2.4.1 Prevalence Population 65
5.2.4.2 Prescription Population 66
5.2.5 Drivers for the Chemotherapy Induced Nausea and Vomiting Market 67
5.2.5.1 Increase Uptake of Novel Anti-Emetics Such As Emend 67
5.2.5.2 Increase in Cancer Prevalence 68
5.2.6 Restraints for the Chemotherapy Induced Nausea and Vomiting Market 68
5.2.6.1 Patent Expiry of Leading Anti-Emetics Such As Aloxi, Emend and Anzemet 68
5.2.6.2 Better Chemotherapy Drugs with Low or Minimal Emetic Risk 68
5.2.7 Geographical Landscape 69
5.3 Cancer Pain Market 72
5.3.1 Introduction 72
5.3.2 Revenue 73
5.3.3 Annual Cost of Therapy 75
5.3.4 Treatment Usage Patterns 77
5.3.4.1 Diseased Population 79
5.3.4.2 Treatment Seeking Population 80
5.3.4.3 Diagnosed Population 82
5.3.4.4 Prescription Population 83
5.3.5 Drivers for the Cancer Pain Market 84
5.3.5.1 Increasing Treatment Seeking, Diagnosis and Prescription Rate Will Drive the Market 84
5.3.5.2 New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration 84
5.3.6 Restraints for the Cancer Pain Market 84
5.3.6.1 Concerns over the Risks of Addiction Related to Drug Therapy Will Affect the Prescription Rate 84
5.3.7 Geographical Landscape 85
5.4 Chemotherapy Induced Anemia Market 88
5.4.1 Introduction 88
5.4.2 Revenue 89
5.4.3 Annual Cost of Therapy 91
5.4.4 Treatment Usage Patterns 93
5.4.4.1 Prevalence Population 95
5.4.4.2 Prescription Population 96
5.4.5 Drivers for the Chemotherapy Induced Anemia Market 97
5.4.5.1 Greater Efficacy of Combination Therapies (Erythropoietins and Iron IVs) 97
5.4.5.2 High Unmet Need in Terms of Drug Safety 98
5.4.6 Restraints for the Chemotherapy Induced Anemia Market 98
5.4.6.1 Restrictions on the Use of Erythropoietins 98
5.4.6.2 Declining Incidence of CIA in the Chemotherapy Patient Population 99
5.4.6.3 Entry of Biosimilars 99
5.4.7 Geographical Landscape 99
5.5 Chemotherapy Induced Neutropenia Market 104
5.5.1 Introduction 104
5.5.2 Revenue 105
5.5.3 Annual Cost of Therapy 107
5.5.4 Treatment Usage Patterns 109
5.5.4.1 Prevalence Population 111
5.5.4.2 Prescription Population 112
5.5.5 Drivers for the Chemotherapy Induced Neutropenia Market 113
5.5.5.1 Higher Uptake of G-CSFs 113
5.5.5.2 Increased Affordability Due to Entry of Biosimilars 114
5.5.6 Restraints for the Chemotherapy Induced Neutropenia Market 114
5.5.6.1 Patent Expiries of Leading G-CSFs 114
5.5.6.2 Weak Pipeline 114
5.5.7 Geographical Landscape 115
5.6 Bone Metastases Market 119
5.6.1 Introduction 119
5.6.2 Revenue 119
5.6.3 Annual Cost of Therapy 121
5.6.4 Treatment Usage Patterns 123
5.6.4.1 Prevalence Population 125
5.6.4.2 Prescription Population 126
5.6.5 Drivers for the Bone Metastases Market 128
5.6.5.1 Increased Uptake of Monoclonal Antibodies such as Denosumab 128
5.6.5.2 Increasing Prevalence of Cancer and Resulting Population Suffering From Bone Metastases 128
5.6.6 Restraints for the Bone Metastases Market 128
5.6.6.1 Patent Expiry of Leading Bisphosphonates such as Zometa and Boniva 128
5.6.7 Geographical Landscape 128
6 Cancer Supportive Care Products Market: Geographical Landscape 133
6.1 The US 133
6.1.1 Revenue 133
6.1.2 Average Annual Cost of Therapy 134
6.1.3 Therapeutic Segmentation 136
6.2 Top Five Countries of Europe 137
6.2.1 Revenue 137
6.2.2 Average Annual Cost of Therapy 139
6.2.3 Therapeutic Segmentation 141
6.2.4 Geographic Segmentation 143
6.3 Japan 144
6.3.1 Revenue 144
6.3.2 Average Annual Cost of Therapy 146
6.3.3 Therapeutic Segmentation 148
7 Cancer Supportive Care Products Market: Pipeline Analysis 150
7.1 Introduction 150
7.1.1 Research and Development Pipeline – Oral Mucositis and Dry Mouth 152
7.1.2 Research and Development Pipeline – Chemotherapy Induced Nausea and Vomiting 153
7.1.3 Research and Development Pipeline – Cancer Pain 154
7.1.4 Research and Development Pipeline – Chemotherapy Induced Anemia 156
7.1.5 Research and Development Pipeline – Chemotherapy Induced Neutropenia 157
7.1.6 Research and Development Pipeline – Bone Metastases 158
7.2 Profiles of Promising Drugs in the Cancer Supportive Care Products Market 160
7.2.1 Xgeva/Prolia (denosumab) – Bone Metastases 160
7.2.1.1 Product Description 160
7.2.1.2 Mechanism of Action 160
7.2.1.3 Clinical Study Details 160
7.2.2 Alpharadin – Bone Metastases 161
7.2.2.1 Product Description 161
7.2.2.2 Mechanism of Action 161
7.2.2.3 Clinical Study Details 161
7.2.3 MAXY-G34 – Chemotherapy Induced Neutropenia 162
7.2.3.1 Product Description 162
7.2.3.2 Mechanism of Action 162
7.2.3.3 Clinical Study Details 162
7.2.4 Lactermin – Oral Mucositis 163
7.2.4.1 Product Description 163
7.2.4.2 Mechanism of Action 163
7.2.4.3 Clinical Study Details 164
7.2.5 Xen2174 – Cancer Pain 164
7.2.5.1 Product Description 164
7.2.5.2 Mechanism of Action 164
7.2.5.3 Clinical Study Details 165
7.2.6 Tectin – Cancer Pain 165
7.2.6.1 Product Description 165
7.2.6.2 Mechanism of Action 165
7.2.6.3 Clinical Study Details 166
7.2.7 NasalFent – Cancer Pain 166
7.2.7.1 Introduction 166
7.2.7.2 Mechanism of Action 166
7.2.7.3 Clinical Study Details 167
8 Cancer Supportive Care Products Market: Competitive Landscape 168
8.1 Market Share Analysis 168
8.2 Competitive Profiling 169
8.2.1 Amgen 169
8.2.1.1 Business Description 169
8.2.1.2 Products Portfolio 169
8.2.1.3 Pipeline Portfolio 171
8.2.1.4 SWOT Analysis 171
8.2.2 Johnson & Johnson 172
8.2.2.1 Business Description 172
8.2.2.2 Products Portfolio 173
8.2.2.3 Pipeline Portfolio 173
8.2.2.4 SWOT Analysis 174
8.2.3 F. Hoffmann-La Roche 175
8.2.3.1 Business Description 175
8.2.3.2 Products Portfolio 176
8.2.3.3 Pipeline Portfolio 176
8.2.3.4 SWOT Analysis 177
8.2.4 Novartis 177
8.2.4.1 Business Description 177
8.2.4.2 Products Portfolio 178
8.2.4.3 Pipeline Portfolio 178
8.2.4.4 SWOT Analysis 179
8.2.5 Pfizer 180
8.2.5.1 Business Description 180
8.2.5.2 Products Portfolio 181
8.2.5.3 Pipeline Portfolio 181
8.2.5.4 SWOT Analysis 182
9 Cancer Supportive Care Products Market: Deals Landscape 184
9.1 M&A and Licensing Agreements 184
9.1.1 Deals by Year 184
9.1.2 Deals by Deal Type 185
9.1.3 Deals by Indication 186
9.1.4 Deals by Value ($m) 187
9.1.5 Deals by Geography 188
9.1.6 Major Acquisitions in the Cancer Supportive Care Products Market 190
9.1.6.1 Amgen Acquires Dompe Biotec 190
9.1.7 Major Licensing Agreements in the Cancer Supportive Care Products Market 190
9.1.7.1 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca 190
9.1.7.2 Celgene Enters Into Co-Development Agreement with Acceleron Pharma 191
9.1.7.3 Amgen Enters Into Co-Development Agreement with Takeda Pharmaceutical 191
9.1.7.4 Algeta Signs Licensing Agreement with Bayer 192
9.1.7.5 Amgen Enters Into License Agreement with Ortho-McNeil-Janssen 192
10 Cancer Supportive Care Products Market: Appendix 193
10.1 Market Definitions 193
10.2 Abbreviations 194
10.3 Research Methodology 195
10.3.1 Coverage 195
10.3.2 Primary Research 196
10.3.3 Forecasts 197
10.3.3.1 Epidemiology-based Forecasting 197
10.3.4 Expert Panel Validation 200
10.4 Contact Us 200
10.5 Disclaimer 200
10.6 Sources 200